FDA issues warning on AAA (abdominal aortic aneurysms) endovascular graft devices
This article was originally published in Clinica
The US FDA is warning physicians that serious problems, such as rupture and vessel damage, have occurred with the two endovascular graft devices now on the market for treatment of abdominal aortic aneurysms (AAA). The agency has not called for any change in how Guidant's Ancure System or Medtronic's AneuRx System are used. But its April 27 public health notification recommends that doctors make sure that all implanted patients are carefully followed and receive periodic follow-up imaging.
You may also be interested in...
Biopharma was an attractive investment in 2020 and fundamentals are unchanged in 2021, including the pandemic’s work-at-home requirements, which allowed more companies to go public faster.
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.